NVAX logo

NOVAVAX INC

NVAXNASDAQ
πŸ† #2145 by market capUS Equity
$7.49β€”
Last available close Β· quote unavailable
πŸ””
Track NVAX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 12.1%
14dβ–Ό 30.6%
30dβ–Ό 22.7%
ytdβ–² 11.3%
1yβ–² 15.9%
🏦Market Cap
$1.27B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-61.6%
Declining
πŸ“ŠGross Margin
79.2%
High
πŸ’΅FCF Margin
25.6%
Strong
βš–οΈP/S Ratio
3.2x
Fair
Otter Score
52
Fair

Trading Snapshot

Day Range
β€”
52-Week Range
$6.20 – $13.39
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
164.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$1.12B
Last Q Revenue
$68M
P/E Ratio
β€”
P/S Ratio
3.2x
EPS (TTM)
$-1.54
Dividend Yield
β€”
Dilution (1yr)
+8.0%
NVAX logo

NOVAVAX INC

NVAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1Bβ–² +64.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.7%β–² +33.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$563Mβ–Ό βˆ’326.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$250Mβ–² +149.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
173.1Mβ–² +8.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$8Mβ–Ό βˆ’$308M YoY
StockOtter Β· stockotter.space

About NOVAVAX INC

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
52/100
Analyst data unavailable.

Latest News & Updates

News unavailable.